Ebola Bundibugyo, WHO updates emergency guidance on the use of the Ervebo vaccine

On September 1, 2026, the World Health Organization published updated emergency guidance with recommendations on the potential use of Ervebo, the only currently authorized Ebola vaccine, as shown in the organization’s news section. The document forms part of the response to the Bundibugyo virus outbreak confirmed in May in the Democratic Republic of the Congo and Uganda.

The technical point explaining why specific guidance was needed is this: for the Bundibugyo species, there are currently no vaccines or specific treatments, while tests are underway on candidates considered promising. Ervebo is authorized for a different species of the virus. The WHO’s indications therefore concern use under emergency conditions, and should be read as recommendations from the international health authority, not as the availability of proven protection against this species. This newspaper reports the organization’s position and does not formulate any indication of its own.

The timeline of the response

The WHO was alerted on May 5, 2026 to a high-mortality outbreak in the Mongbwalu health zone, in Ituri province, with deaths including among health workers, according to the page dedicated to the emergency. The outbreak was subsequently declared a public health emergency of international concern, the classification set out in the International Health Regulations, and a second emergency committee met on August 18, 2026.

On September 1, the WHO Director-General spoke at a high-level briefing with Member States dedicated to the outbreak response: the same day the guidance was published. The coincidence of dates indicates the scope of the initiative — an operational update aimed at countries, not a scientific announcement.

On the matter of sources it must be stated clearly: all the material supporting this account traces back to the organization itself, including the emergency briefs compiled by OCHA, which are based on WHO data. The news currently comes from a single source (the World Health Organization); no independent confirmation is available.

Why the viral species changes everything

In current communication “Ebola” functions as a single name. It is not: virus species have different lethality, transmission dynamics and — above all — different countermeasures. A vaccine authorized for one species does not automatically transfer its efficacy to another, and the difference is not a matter of nomenclature but the reason why, in this outbreak, the WHO had to write emergency guidance rather than simply activate an existing protocol.

What we don’t know

The material available today does not contain an update on the case and death toll, nor the breakdown between the two countries involved: for this reason no epidemiological figure appears here. We do not know the detailed operational content of the recommendations, nor which population groups they target. We do not know what stage the tests on vaccine candidates for the Bundibugyo species have reached, nor who is conducting them.

Finally, there is no indication of any decision by a regulatory body extending Ervebo’s authorization to this species: the WHO guidance concerns potential emergency use, which is a category distinct from marketing authorization.